Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $360.00 Price Target at BMO Capital Markets

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target increased by BMO Capital Markets from $300.00 to $360.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target points to a potential upside of 11.82% from the company’s current price.

ALNY has been the topic of a number of other research reports. Royal Bank Of Canada upped their price target on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research report on Friday, March 21st. HC Wainwright reiterated a “buy” rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. JPMorgan Chase & Co. increased their target price on shares of Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the company an “overweight” rating in a research report on Thursday, June 12th. Citigroup boosted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Finally, Chardan Capital upped their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and twenty have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $335.32.

Alnylam Pharmaceuticals Trading Down 0.9%

ALNY opened at $321.94 on Tuesday. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98. Alnylam Pharmaceuticals has a fifty-two week low of $205.87 and a fifty-two week high of $326.03. The company’s 50 day moving average price is $282.80 and its two-hundred day moving average price is $262.36. The firm has a market capitalization of $41.98 billion, a price-to-earnings ratio of -154.04 and a beta of 0.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. Alnylam Pharmaceuticals’s revenue for the quarter was up 20.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.16) EPS. As a group, research analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the company’s stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the transaction, the chief executive officer now directly owns 48,948 shares of the company’s stock, valued at $14,978,088. This represents a 28.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Larson Financial Group LLC raised its holdings in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 73 shares during the last quarter. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $27,000. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $28,000. Whipplewood Advisors LLC lifted its position in Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 71 shares in the last quarter. Finally, Bessemer Group Inc. lifted its position in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 69 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.